The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

U.S. pharmaceutical giant Merck has warned that existing tariffs imposed by the Trump administration will cost the company an ...

Switzerland’s president is lobbying Trump administration officials in Washington this week, as concern mounts over the double ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products ...

Roche (RHHBY) expects an increase in Group sales in the mid single digit range at CER. Core earnings per share are targeted to develop in the ...

The French lender on Thursday posted a net profit for the three months ended March 31 of 2.95 billion euros, equivalent to about $3.34 billion. That was in line with company-compiled consensus ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned. | Big Pharma ...